Forte Biosciences Inc Dossier - Source-backed chat

Forte Biosciences Inc

FBRXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)2.05

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $76.99Price as of 26 Aug 2026

Data confidenceNot applicable

Market Cap $1.6B

Enterprise Value $1.6B

Shares Outstanding 20.5M diluted

Next Earnings Date14 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Forte Biosciences is a clinical-stage biopharmaceutical company focused on developing its lead candidate, FB102, a proprietary anti-CD122 monoclonal antibody. Following the failure of its previous candidate FB-401, Forte has successfully pivoted to FB102, which targets the IL-2/IL-15 receptor beta subunit (CD122) to inhibit T-cell and NK-cell-mediated autoimmune responses. The company is positioned for a catalyst-rich 2026, with multiple clinical readouts expected across celiac disease, vitiligo, and alopecia areata. Backed by a significantly strengthened balance sheet following a $172.5 million gross equity raise in April 2026, Forte has extended its cash runway to support operations through key clinical inflection points. While pipeline concentration risk remains high, the multi-billion-dollar market potential of its target indications and strong Phase 1b proof-of-concept data in celiac disease present an attractive risk-reward profile for biotechnology investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$61.00

Mean target$73.80

High · most bullish analyst$77.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$10.0020%

In the bear case, the Phase 2 celiac disease trial fails to meet its primary efficacy endpoints or exhibits safety concerns, such as severe NK cell depletion or off-target toxicities. Additionally, the Phase 1b trials in vitiligo and alopecia areata fail to show meaningful clinical efficacy. Given Forte's sole reliance on FB102, negative clinical readouts would severely damage the company's valuation, leading to a significant decline in the stock price and forcing the company to restructure or seek alternative strategic options.

Base CaseCentral scenario

$66.6050%

In the base case, FB102 achieves positive and statistically significant Phase 2 results in celiac disease, confirming its therapeutic potential and supporting advancement into Phase 3 trials. The Phase 1b vitiligo and alopecia areata trials yield supportive, though perhaps mixed, efficacy signals that warrant further clinical investigation. Forte's strong cash position of over $220 million (pro-forma including the April 2026 capital raise) provides ample runway to advance the celiac program into late-stage development and refine the clinical strategy for other indications. The stock achieves steady appreciation toward consensus analyst targets as clinical milestones are met.

Bull CaseUpside scenario

$75.0030%

In the bull case, FB102 delivers outstanding Phase 2 topline results in celiac disease, demonstrating robust histological and symptom-based efficacy that replicates or exceeds the Phase 1b results (where it achieved a statistically significant VCIEL composite histologic endpoint of p=0.0099). Concurrently, the Phase 1b trials in vitiligo and alopecia areata yield strong positive proof-of-concept data, validating FB102's broad applicability across multiple high-value autoimmune indications. This clinical success triggers a major upward re-rating of the stock, attracting partnership interest from large pharmaceutical companies and positioning Forte to capture a significant share of multi-billion-dollar markets.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong Phase 1b proof-of-concept data in celiac disease demonstrating significant histological benefit (p=0.0099) and mechanistic validation.
Catalyst-rich timeline with multiple clinical readouts expected in 2026 across celiac disease, vitiligo, and alopecia areata.
Robust balance sheet with approximately $220 million in cash (pro-forma) following a successful $172.5 million equity offering in April 2026, providing multi-year runway.
FDA Fast Track Designation granted for FB102 in celiac disease, highlighting the high unmet medical need and accelerating regulatory pathways.
Broad market potential across multiple autoimmune indications representing multi-billion-dollar commercial opportunities.

Key Investment Risks

High pipeline concentration risk, as the company's valuation is almost entirely dependent on the clinical success of a single candidate, FB102.
Clinical trial uncertainty, with the risk that Phase 2 celiac disease results may not replicate the positive signals observed in the smaller Phase 1b study.
Intense competition in the autoimmune space from established therapies and other clinical-stage candidates targeting similar pathways.
Potential safety concerns related to systemic NK cell and T-cell depletion associated with anti-CD122 mechanism of action.

Thesis Invalidation Triggers

Failure of the FB102 Phase 2 celiac disease trial to meet its primary efficacy or safety endpoints.
Inability of the Phase 1b vitiligo or alopecia areata trials to demonstrate sufficient clinical efficacy to justify further development.
Unexpected severe adverse events or toxicities leading to clinical holds or regulatory restrictions on FB102.
Significant delays in clinical trial enrollment or data readouts that exhaust the company's cash runway before key milestones are achieved.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.